Somatic activating mutations of smoothened (SMO), a component of the embryonic sonic hedgehog (SHH) signaling pathway, are found in 3-5% of grade I meningiomas, most of them corresponding to meningothelial meningiomas located at the anterior skull base. By generating different developmental stage-specific conditional activations in mice, we define a restricted developmental window during which conditional activation of Smo in Prostaglandin D2-synthase-positive mesoderm-derived meningeal layer of the skull base results in meningothelial meningioma formation. We show a selective vulnerability of the arachnoid from the skull base to Smo activation to initiate tumor development. This prenatal period and specific topography are correlated to the timing and location of SHH signaling involvement in the formation of craniofacial and meninges patterning, strongly corroborating the hypothesis of a developmental origin for Smo-activated meningiomas. Finally, we provide preclinical in vitro evidence of the efficacy of the SMO-inhibitor Sonidegib, supporting further preclinical and clinical evaluation of targeted treatment for refractory SMO-mutant meningiomas.
Introduction
Meningiomas are the most common primary central nervous system tumors in adults [1] . Treatment algorithms are based on surveillance, surgery, and radiotherapy/radiosurgery [2] . Meningiomas are classified into three prognostic histological groups following the WHO classification: grade I (65-80%), grade II (20-35%, atypical), and grade III (<3%, anaplastic) [1, 2] . Recent advances in the molecular genetics of WHO grade I meningioma have led to the discovery of mutations in several oncogenes, including AKT1, KLF4, SMO, PIK3CA, POLRA2, and TRAF7, all mutually exclusive to mutations in the NF2 tumor suppressor gene involved in at least 50% of meningiomas [3] [4] [5] [6] . Discovery of this mutational landscape enabled the establishment of histological and/or anatomical correlations with specific gene mutations [3, 7, 8] . In a recent series of 775 meningiomas, Clark et al. described Sonic Hedgehog (SHH) pathway-related meningiomas harboring 42 SMO gene mutations (recurrent mutations L412F and W535L in 76% of cases), 5 SUFU mutations and 3 PRKAR1A mutations [4] . These tumors were mostly WHO grade I, meningothelial, and located at the anterior skull base, suggesting a possible link between this potential driver mutation and anatomical site of origin. Indeed, SMO mutations alter the SHH pathway, which plays a critical role in craniofacial patterning during embryonic development, and consequently in the development of meninges at this location [9] . However, it is not clear whether meningioma tumorigenesis is induced by early prenatal deregulation of meningeal embryogenesis or by late postnatal dedifferentiation of mature cells into a stem-like state [4] . In fact, very little is known about the origin and regulation of meningeal development in humans and mice. By generating different tissue and developmental stage-specific conditional knockout mice with neural crest and mesoderm specific promoters, we and others have characterized the embryonic origin of the meninges with those covering the telencephalon being of neural crest origin, and those at the level of the skull base deriving from the cephalic mesoderm [10] [11] [12] . We showed that prostaglandin D2 synthase (PGDS) gene is a specific marker of arachnoidal cells and meningiomas in humans and mice and that PGDS-positive cells of the primitive meningeal layer developed during embryogenesis are the progenitor cells of origin capable of generating meningiomas [12] . Here we demonstrate that mouse meningiomas induced by Smo activation in PGDS-positive cells have the same histological-meningothelial-and anatomical-skull base-characteristics as their human SMO-mutant tumors counterparts. In addition, we have identified a specific temporal window of activation for Smorelated meningioma tumorigenesis, providing clues to the developmental origin of this subgroup of meningiomas. These findings provide new insights in the molecular mechanisms of meningioma formation and support the use of targeted medical therapy for those rare skull base SMOmutant meningiomas that are refractory to surgery and radiotherapy/radiosurgery with high morbidity [13] .
Results

Identification of a restricted developmental temporal window for Smo activation and meningioma vulnerability
To investigate the role of Smo mutation in meningeal tumorigenesis, we generated genetically engineered SmoM2 mice in which activation of the Shh pathway was achieved by Cre-mediated conditional expression of an activated Smoothened allele (SmoM2) [14] . Prenatal activation of Smo was induced by generating 42 PGDSCre;SmoM2 mice where SmoM2 was expressed early (starting at E12.5) at the skull base level in the meningeal precursor cells identified as PGDS-positive cells [12] . After a mean survival of 14.2 months, 9 of 42 (21%) PGDSCre;SmoM2 mice developed meningiomas and 32 (76%) presented foci of meningothelial proliferation, the first manifestation of meningioma tumorigenesis in mice [15] (Table 1 ). All tumor lesions were localized at the skull base level ventral to the brainstem. Histologically, they appeared as meningothelial grade I meningiomas showing the typical aspect of tumoral meningothelial cells with oval nuclei and nuclear clearing disposed in lobules (Fig. 1a-c) .
To analyze the effect of postnatal Smo activation, a cohort of 53 SmoM2 mice was injected with adCre at postnatal day 2 (25 at the convexity-s.d. (subdural)-and 28 at the skull base-t.o.(trans orbitary)-). Forty-nine mice were analyzed after a mean survival of 14.2 months: only one meningothelial meningioma (2%) and 23 (43%) meningothelial proliferations were observed at the skull base (Fig. 1d ). All meningothelial proliferations were located at the skull base level even after injection at the convexity. Interestingly, the four other mice in the cohort died shortly after a mean survival of 2.8 months. All presented typical large cerebellar medulloblastomas composed by sheets of poorly differentiated small cells (Fig. 1e) , without meningothelial proliferation. Our hypothesis is that after sub-dural injection the adCre virus transduced cells in the neuraxis by diffusion through the cerebrospinal fluid. This induced SmoM2 expression in neural progenitors of developing cerebellar cortex, the cell of origin of Shh-activated medulloblastoma representing 25% of this tumor type [16, 17] . Activation of the Hedgehog pathway was confirmed in vivo in both models by immunohistochemical expression of Gli-1 in Smo-related meningothelial proliferations and meningiomas (Fig. 1f, g ). No meningothelial proliferation, meningioma, or medulloblastoma were found in the control cohort of 8 adLacZ-SmoM2 mice. These results defined a restricted developmental window during which conditional activation of Smo in PGDS mesodermderived meningeal layer of the skull base results in meningioma formation. (Fig. 2a, b) . No fluorescence was expressed in expression induced a significant increase in Gli1 (p = 0.005, t-test) and Ptch1 (p = 0.03, t-test) mRNA levels ( Fig. 2e ), the two main target genes of the canonical Shh pathway [18] . In contrast, no difference in Gli1 (p = 0.37, t-test) or Ptch1 (p = 0.77, t-test) mRNA levels was found in the convexity arachnoidal cells (Fig. 2f ). The differences in arachnoid from skull base and convexity region are not intrinsic as growth pattern and mRNA levels of Gli1 and Ptch1 were similar in control/wild-type cells (infected with adLacZ). These results clearly showed a differential response and thus vulnerability to Smo activation according to the location and embryological origin of the meninges, 
LDE-225 (Sonidegib) inhibits Shh pathway and cell proliferation in skull base SmoM2 arachnoidal cells
To obtain preclinical evidence of the efficacy of SMO inhibitors in the treatment of meningiomas, we analyzed the effect of LDE-225 (Sonidegib) on primary arachnoidal cells in culture. Since the pro-proliferative effect of SmoM2 expression was found only in arachnoidal cells of the skull base, all the experiments with Sonidegib were carried out with those cells. Skull base adCre-infected SmoM2 arachnoidal cells were treated with Sonidegib (10 or 100 nM) 1 day after adCre infection. Short-term proliferation assays showed that Sonidegib at 10 nM was able to inhibit the proliferation of adCre-infected SmoM2 cells in terms of cell count (p = 0.02, t-test, Fig. 3a ) although WST1 activity was not significantly decreased (p = 0.41, t-test, Fig. 3b ). There was a significant reduction in Gli1 (p = 0.005, t-test) mRNA expression compared to vehicle (DMSO) treatment, but no difference was observed for Ptch1 mRNA levels (p = 0.71, t-test) (Fig. 3c, d ).
Discussion
Among the nine different histological subtypes of Grade I meningiomas in humans, the unique histological subtypemeningothelial-of SMO-mutant meningiomas supports the view that this oncogenic pathway is critical to the arachnoidal meningeal lineage at the origin of this subtype compared to the fibroblastic subtype. Previous embryologic studies have shown that PGDS-positive primordial meningeal cells arising at E12.5 give rise to meningeal cells of both arachnoid and dura-mater layers at E14.5 (Fig. 4 ) [12] . We previously showed using gentically engineered mouse models that the two major histological subtypes of WHO Grade I meningiomas were inducible by Nf2 inactivation and found in 38% of PGDSCre;Nf2 flox/flox2 mice:
Meningothelial tumors were originating from the arachnoid layer (arachnoid border cells) and fibroblastic tumors were emanating from the dura-mater (dural border cell layer) [12] (Fig. 4) . In contrast, for Smo-related meningeal tumorigenesis, only meningothelial and no fibroblastic meningiomas were found in PGDSCre;SmoM2 mice, thus implying that, unlike PGDS-positive arachnoidal cells, PGDS-positive dura-mater cells are not vulnerable to Smo activation for meningothelial meningioma development (Fig. 4) . All meningiomas found in PGDSCre;SmoM2 mice displayed histological features strikingly similar to human SMO-mutant meningiomas. To explore the postnatal developmental window for tumor development, we have previously reported a model with adCre injection in the subdural space of newborn mice and shown that Nf2 loss in very early postnatal meningeal cells was sufficient to induce meningioma formation (WHO Grade I meningiomas of different histological subtypes in 23% of mice) [12] . In contrast to Nf2-related tumorigenesis, the absence of meningioma in adCre;SmoM2 mice, corresponding to an early postnatal activation, and the selective finding of meningothelial (WHO Grade I) meningiomas at the skull base level of PGDSCre;SmoM2 mice suggest that embryonic activation of Smo in the arachnoidal meningeal layer is necessary for Smo-related meningioma tumorigenesis (Fig. 4) . The temporal developmental window in which Smo mutation culminates in meningioma formation is more restrictive for Smo compared to Nf2 where the window for tumor initiation is wider, encompassing the embryonic and early postnatal periods [12] . The benign nature and unique spatial location of these meningiomas is also reflected by the slight in vitro proliferative advantage and selective sensitivity to Sonidegib of SmoM2-expressing arachnoidal cells of the skull base versus the convexity and by the presence of meningothelial proliferation restricted to the skull base level regardless of the injection site of adCre, respectively. Taken together, these results indicate that Smo activation is necessary and sufficient to induce meningioma development at the skull base level in a restricted temporal window during the prenatal period starting at E12.5, strongly arguing in favor of the developmental nature of this subgroup of meningiomas and supporting the hypothesis that the developmental stage of arachnoidal cells determine their susceptibility to tumor-initiating alterations, This hypothesis and the predominance of human SMO-mutated meningiomas at the median skull base level are also sustained by the fact that SHH is the main embryonic signaling pathway implicated in ventral craniofacial development by promoting rapid cell expansion of the facial mesenchyme, quickly followed by a transition to a terminally differentiated state of the connective tissue of the face and skull [16, 19, 20] . It has already been shown that targeted disruption of Smo in mice affect appropriate growth and patterning in the early facial primordial, while its constitutive activation (Wnt1-Cre;SmoM2) produces hyperplasia of the facial processes and gross disorganization, with a failure of most craniofacial skeletogenesis [9] . Identically, in ameloblastoma, a locally destructive tumor occurring during tooth development, a relation between anatomical site and driver gene mutation has also been recently shown: Mutations in SMO are common in ameloblastomas arising from the maxilla whereas BRAF mutations are predominant in tumors of the mandible [21] . This anatomical specificity for odontogenic development in the upper or lower dentition is likely to reflect distinctive developmental pathways based on spatial temporal and/or cell type-specific cues. Finally, similar to our approach and results, Ohli et al. [22] have observed in a Math1-CreER Curiously, no PGDSCre;SmoM2 mouse suffered from symptomatic meningioma before 15 months of age. This is likely due to slow, indolent tumor growth with no clinical impact until late in life, like in humans, where SMO-mutant meningiomas are also diagnosed later in life (mean age of 55 years) [13] . In a recent paper, an integrated model of the growth dynamics of benign meningiomas using radiocarbon retrospective birth dating was provided for the first time [23] . In their series, the mean lifetime of WHO grade I meningiomas was 22.1 ± 6.5years (whereas atypical WHO grade II meningiomas originated 1.5 ± 0.1years) prior to surgery. Assuming an additional period of time between the first initiating mutation in a single meningeal cell and the time a microscopic lesion can be measured, in addition to the fact that olfactory groove meningiomas (like most SMO-mutated meningiomas [13] ) can remain silent for a long time despite a very large volume, then we should reconsider our concepts on the natural history of grade I meningiomas. In contrast, other developmental malignant tumors of the central nervous system, such as neuroblastomas, SMO-mutant or SHH-activated medulloblastomas, and malignant rhabdoid tumors generally occur during infancy or childhood [16, 24] . The restricted early developmental time window for Smarcb1 loss to promote malignant rhabdoid tumor formation and vulnerability to additional Nf2 tumor suppressor gene mutations resulting in benign schwannoma formation later in life, provides another striking example of close interrelationship between timing of driving mutations, tumor tissue of origin, and clinical behavior [25] .
From a prognostic and therapeutical point of view, despite their bland histologic appearance, we have shown that SMO mutation is associated with poorer prognosis within the olfactory groove meningiomas subgroup with several patients showing serious clinical morbidity (blindness, pituitary gland dysfunction) and late recurrences [13] . These recurrences were observed despite optimal available treatments, suggesting that SMO inhibitors would be clinically useful in daily practice. SMO inhibitors are under clinical evaluation for SHH-mutated medulloblastoma [26] and routinely used in metastatic basal cell carcinoma [27] . Our study provides the first preclinical in vitro evidence of the efficiency of Sonidegib for the treatment of SMOmutant meningiomas. Sonidegib significantly inhibited both Shh pathway activation and growth in SmoM2 activated skull base arachnoidal cells at nanomolar concentrations. Thus, we provide a rationale for clinical trials evaluating SMO inhibitors in the treatment of refractory SMO-mutant meningiomas. A multicenter phase II study of Vismodegib is now recruiting patients with progressive or recurrent SMO-mutant meningiomas (NCT02523014, clinicaltrials.gov).
Materials and methods
Mice
Rosa26-lox-STOP-lox-SmoM2 mice (called SmoM2 mice in this paper) were purchased from the Jackson Laboratory. In this model, a conditional allele of SmoM2 with a C-terminal YFP tag is targeted into the ubiquitously expressed Rosa26 locus, after a lox-P flanked polyadenylation stop sequence cassette. In presence of Cre recombinase, SmoM2 gene is expressed and encodes for a mutant form of protein Smo previously identified in human basal cell carcinoma [28] . In this mutant allele, an activating mutation (W535L) in the seventh transmembrane domain results in ligandindependent constitutive activation of the Shh pathway in target tissue [14] .
To To induce prenatal activation of Shh in meningeal precursor cells, SmoM2 mice were bred with homozygous PGDSCre mice to obtain hemizygous PGDSCre;SmoM2 mice [12] . In this model, Cre recombinase is expressed selectively in PGDS-positive cells and is able to induce the expression of the SmoM2 gene. All animal care and experimentation reported herein were conducted in compliance with the guidelines and with the specific approval of the Institutional Animal Care and Use Committee of the French Department of Agriculture. 
Histopathology and immunohistochemistry
Mice were monitored closely and killed when seriously ill or at 15 months. To preserve the arachnoidal layer, the head was fixed in formalin in toto, decalcified, and sliced coronally before embedding in paraffin as previously described [29] . The terminology used for the description of the meningothelial lesions in the mouse models is based on the WHO classification of human tumors with adaptations [30] . The term "meningothelial hyperplasia" is not used, as in humans where it refers to the proliferation of reactive, normal arachnoidal cells. "Meningothelial proliferation" refers to very small (microscopic) lesions composed of meningothelial cells that represent early tumor formation. "Meningioma" refers to a larger meningothelial lesion, with features similar to a WHO grade I meningioma in humans.
Immunohistochemical staining was performed on 5-μm paraffin sections. For antigen retrieval, after pressure boiling in 1 mM EDTA (pH 8.0) for 30 min, sections were blocked in 10% serum followed by incubation with primary antibody. Biotinylated secondary antibodies were used at 1:200 (Gli-1, ab151796, Abcam). Stainings were developed using Vectastain ABC system and DAB substrate kit (Vector Labs). Normal mouse arachnoid was used as positive control. In vitro functional assays
Arachnoidal cells culture
Proliferation assay
After infection, arachnoidal cells were passaged, seeded at a concentration of 15,000 cells/mL in triplicate in 12-well plates, and counted manually using a Malassez cell counting chamber 1, 4, and 7 days after plating. Arachnoidal cells were seeded at a concentration of 3000 cells/100 µL in triplicate in 96-well plates. WST1 assay was performed by adding 10% WST1 reagent (Roche, Indianapolis, Indiana, USA) in the medium and measuring absorbance after 3 h using a Spectromax M4 for wavelengths 450-620 nm.
Senescence assay
SA β-galactosidase staining was performed on infected arachnoidal cells [31] .
Apoptosis assay
After infection, arachnoidal cells were passaged, stained according to a standardized Annexin V FITC-Propidium Iodide protocol (Thermo Fisher Scientific, Waltham, MA, USA) and sorted using flow cytometry analysis (FACSDiva, BD Biosciences, San Jose, CA, USA).
RNA extraction and RT-qPCR
After infection, cells were passaged and seeded in 12-well plates. RNA was extracted 48 h after passage using a Nucleospin RNA kit (Macherey-Nagel, Germany) and quantified using Nanodrop (Thermo Fisher, Villebon sur Yvette, France). RNA was retrotranscribed using the Maxima First Strand cDNA Synthesis Kit (Thermo Fischer). The cDNA obtained was used as a template for the determination of Gli1 and Ptch1 mRNA expression by qPCR on a Lightcycler® 96 (Roche, Bâle, Switzerland) using a Quantifast assay (Qiagen, Hilden, Germany). The ΔCt method was applied to normalize the mRNA levels using the expression of glucuronidase-β. The primer sets for qPCR were designed with the Roche design center (www. universalprobelibrary.com) (Supplementary Table S2 ).
LDE-225 (Sonidegib) treatment
Sonidegib, a selective inhibitor of SMO, was provided by Novartis (MTA 43219). Proliferation assays and Gli1 and Ptch1 expression analyses were performed with Sonidegib at different concentrations (10 and 100 nM) in triplicate.
Statistical analysis
Student's t-tests were used in proliferation assays and mRNA level analyses. The distribution of categorical variables was compared with Fisher's exact test. All tests were two-sided and a p-value of ≤0.05 was considered to be statistically significant. Statistical analyses were performed using Statview version 5.0 software (SAS Institute, Cary, NC, USA).
